Source comparison
MOTS-c vs Tesofensine — Mechanism & Research Comparison
Research from the University of Southern California identified MOTS-c as the first known mitochondrial-encoded peptide that directly regulates metabolic homeostasis. It encodes within mitochondrial DNA and crosses into the nucleus to influence gene expression
This comparison does not assign a generated winner or score.
- Research from the University of Southern California identified MOTS-c as the first known mitochondrial-encoded peptide that directly regulates metabolic homeostasis. It encodes within mitochondrial DNA and crosses into the nucleus to influence gene expression tied to insulin sensitivity and glucose metabolism. Tesofensine, meanwhile, was developed by Novo Nordisk as a CNS-active monoamine reuptake inhibitor for Alzheimer's and Parkinson's, but Phase II trials revealed 10–12% mean body weight reduction at doses where cognitive benefit was minimal. Turning a failed neurological therapy into one of the most potent appetite suppressants in clinical development.
- Our team has reviewed research across both compounds extensively. The fundamental difference isn't just what they do. It's where and how they act. MOTS-c works at the mitochondrial and nuclear level to shift how cells produce and use energy. Tesofensine works in the synaptic cleft to extend the action of dopamine, norepinephrine, and serotonin. Neurotransmitters that regulate hunger, motivation, and thermogenesis.
- What's the difference between MOTS-c and tesofensine?
- MOTS-c is a 16-amino-acid mitochondrial-derived peptide that enhances insulin sensitivity, activates AMPK signaling, and improves skeletal muscle glucose uptake. Functions tied to metabolic flexibility and endurance rather than appetite. Tesofensine is a synthetic small molecule that inhibits reuptake of dopamine, norepinephrine, and serotonin in the CNS, producing appetite suppression and increased energy expenditure through central mechanisms. MOTS-c targets cellular metabolism; tesofensine targets neurochemical signaling.
- Yes, both compounds appear in metabolic research contexts. But MOTS-c is studied for insulin resistance, mitochondrial dysfunction, and age-related metabolic decline, while tesofensine is studied as a pharmacological weight-loss agent with CNS activity. The overlap is outcome (improved metabolic markers), not mechanism. This article covers how each compound works at the molecular level, what existing clinical and preclinical data show, and where their research applications diverge. We'll clarify why one doesn't replace the other and what combining them would actually mean from a regulatory and safety perspective.